Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

Recruiting

Conditions: Mitochondrial Disorders
Mitochondrial Genetic Disorders
Mitochondrial Diseases
Disorder of Mitochondrial Respiratory Chain Complexes
Deletion and Duplication of Mitochondrial DNA

First Posted Date: 2012-09-27

Last Posted Date: 2022-08-01

Lead Sponsor: Columbia University

Target Recruit Count: 1000

Registration Number: NCT01694940

Locations: 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 14 locations

The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)

Conditions: Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)

First Posted Date: 2012-09-27

Last Posted Date: 2022-08-01

Lead Sponsor: Columbia University

Target Recruit Count: 10

Registration Number: NCT01694953

Locations: 🇺🇸
Columbia University, New York, New York, United States

HIV Prevention for Injecting Drug Users in Kazakhstan

Phase 2

Completed

Conditions: HIV
AIDS

Interventions: Behavioral: Couples Based HIV/STI Risk Reduction Intervention (CHSR)
Behavioral: Renaissance Wellness Promotion (WP)

First Posted Date: 2012-09-21

Last Posted Date: 2014-02-27

Lead Sponsor: Columbia University

Target Recruit Count: 600

Registration Number: NCT01690442

Locations: 🇰🇿
Global Health Research Center of Central Asia, Almaty, Kazakhstan

Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders

Not Applicable

Completed

Conditions: Substance-Related Disorders
Sexually Transmitted Diseases
Unsafe Sex

Interventions: Behavioral: PACT
Behavioral: TAU

First Posted Date: 2012-09-21

Last Posted Date: 2018-07-18

Lead Sponsor: Columbia University

Target Recruit Count: 480

Registration Number: NCT01690494

Locations: 🇺🇸
Columbia University, New York, New York, United States

Optical Tomographic Imaging of Infantile Hemangiomas

Completed

Conditions: Infantile Hemangioma

First Posted Date: 2012-08-28

Last Posted Date: 2018-08-06

Lead Sponsor: Columbia University

Target Recruit Count: 15

Registration Number: NCT01673971

Locations: 🇺🇸
Columbia University Medical Center / Department of Dermatology, New York, New York, United States

Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children

Not Applicable

Completed

Conditions: Influenza

Interventions: Other: Text Message
Other: Written reminder

First Posted Date: 2012-08-10

Last Posted Date: 2015-08-07

Lead Sponsor: Columbia University

Target Recruit Count: 660

Registration Number: NCT01662583

Locations: 🇺🇸
Columbia University, New York, New York, United States

A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers

Phase 2

Terminated

Conditions: Recurrent Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Cisplatin
Drug: Doxorubicin

First Posted Date: 2012-08-08

Last Posted Date: 2017-03-10

Lead Sponsor: Columbia University

Target Recruit Count: 4

Registration Number: NCT01659554

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

Phase 1

Completed

Conditions: Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Bendamustine
Drug: Neulasta

First Posted Date: 2012-08-06

Last Posted Date: 2020-07-17

Lead Sponsor: Columbia University

Target Recruit Count: 71

Registration Number: NCT01657331

Locations: 🇺🇸
Center for Lymphoid Malignancies at CUMC, New York, New York, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease

Phase 2

Withdrawn

Conditions: Glycogen Storage Disease Type II

Interventions: Other: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding

First Posted Date: 2012-08-03

Last Posted Date: 2015-04-13

Lead Sponsor: Columbia University

Registration Number: NCT01656590

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Metformin
Drug: Erlotinib

First Posted Date: 2012-07-26

Last Posted Date: 2017-08-30

Lead Sponsor: Columbia University

Target Recruit Count: 8

Registration Number: NCT01650506

Locations: 🇺🇸
Columbia University, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy